Bio-Techne Corp
TECH
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
50.6% downsideOvervalued by 50.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.09 Billion |
|---|---|
| Enterprise Value | $8.21 Billion |
| Dividend Yield | $0.32 (0.62%) |
| Earnings per Share | $0.47 |
| Beta | 1.41 |
| Outstanding Shares | 155,893,000 |
Return
| Return on Equity | 5.25% |
|---|---|
| Return on Assets | 4.30% |
| Return on Invested Capital | 6.48% |
Valuation & Multiples
| P/E Ratio | 73.53 |
|---|---|
| PEG | 58.34 |
| Price to Sales | 7.26 |
| Price to Book Ratio | 3.91 |
| Enterprise Value to Revenue | 6.78 |
| Enterprise Value to EBIT | 52.84 |
| Enterprise Value to Net Income | 74 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.8516▲ 87.97% |
|---|---|
| Total Calls | 621,200▼ 24.35% |
| Total Puts | 1,771,400▲ 9.39% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 113.83%▲ 3.55% |
|---|---|
| Total Invested | $9.29B▼ 8.13% |
| Investors Holding | 599▼ 9.00% |
ESG Score
No data
About Bio-Techne Corp
2,100 employees
CEO: Charles Kummeth Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems , No...
Relevant Senate Committees
This committee provides critical analysis and 'revenue estimates' for all tax legislation. Its technical expertise and reports directly influence corporate tax structures, capital investment incentives, and the overall tax burden on Bio-Techne.
This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy directly impact Bio-Techne's profitability and investment, while Medicare pricing influences the broader healthcare market for its clinical products.
This committee directly allocates discretionary federal spending. Its subcommittees determine precise funding for scientific research (e.g., NIH, NSF) and healthcare programs, which directly impacts Bio-Techne's market and R&D landscape.
This committee directly regulates key agencies like the FDA (critical for diagnostic product approvals) and NIH (a major funder of biomedical research, a market for Bio-Techne's research products). It also influences labor laws impacting manufacturing costs.
This committee's oversight of intellectual property (IP) laws is critical for a biotechnology company like Bio-Techne, which relies heavily on patents. Its antitrust jurisdiction also influences M&A activities within the biotech sector.
The description explicitly mentions 'biotech stocks' as having high risks for informational asymmetry due to classified briefings on global threats. This could include biosecurity, pandemics, or other intelligence directly impacting the biotechnology sector.